Record H1 2026 net sales of $3.1B, up 24.6% year-over-year, with double-digit growth across all segments and geographies. Core EBITDA margin expanded to 25.6%, and full-year net sales growth guidance was raised to 19%-21%.Based on Galderma Group AG [GALD] Q2 2026 Audio Transcript — Jul. 23 2026This…
Record H1 2026 net sales of $3.1B, up 24.6% year-over-year, with double-digit growth across all segments and geographies. Core EBITDA margin expanded to 25.6%, and full-year net sales growth guidance was raised to 19%-21%.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
